• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
NBIX

NBIX

Neurocrine Biosciences, Inc.

NASDAQHealthcareBiotechnologyUS

USD165.11

+10.27 (+6.63%)

Rating:A

Company Profile

CEO

Kyle W. Gano

IPO Date

1996-05-23

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$155.53

Prev. Close

$154.84

Day Low

$155.12

Day High

$165.81

52W Low

$122.14

52W High

$165.81

Market Cap

$16.60B

Volume

1.94M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

11.8%

Avg Negative

12.8%

Avg Neutral

75.5%

News Feed

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results

PRNewsWire·7/19/2021·↑ positive

Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference

PRNewsWire·7/8/2021·↑ positive

Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

PRNewsWire
·6/1/2021
·↓ negative

Neurocrine Biosciences: Pandemic Pressures And Few Pipeline Catalysts Continue To Weigh On NBIX

Seeking Alpha·5/26/2021·↑ positive

Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference

PRNewsWire·5/11/2021·↓ negative

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/5/2021·↓ negative

Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Miss Estimates

Zacks Investment Research·5/5/2021·↑ positive

Neurocrine Biosciences Reports First Quarter 2021 Financial Results

PRNewsWire·5/5/2021·↓ negative

Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference

PRNewsWire·5/4/2021·↑ positive

Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week

PRNewsWire·5/3/2021·↑ positive